Drug Trial Radar · NCT01239797
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
646
Actual
Start
Jun 20, 2011
Primary completion
Sep 2, 2014
Study completion Apr 21, 2021
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Nov 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
Conditions
- Lymphoma
- Multiple Myeloma
Interventions
LenalidomideDrug
Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
DexamethasoneDrug
Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Dexamethasone (Oral)Drug
On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug. On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Dexamethasone (IV)Drug
On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Elotuzumab (BMS-901608; HuLuc63)Biological
Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Progression Free Survival (PFS)Time frame: From randomization up to 326 events (up to approximately 38 months)
- Objective Response Rate (ORR)Time frame: From randomization up to approximately 38 months
Locations
216 sites in 23 countries. Site status is shown where the registry gives one.
Northwest Alabama Cancer Center, Pc
Muscle Shoals, Alabama
Acrc/Arizona Clinical Research Center, Inc.
Tucson, Arizona
Local Institution
Berkeley, California
Local Institution
Burbank, California
Compassionate Cancer Res Grp
Corona, California
Local Institution
Corona, California
San Diego Pacific Oncology& Hematology Associates, Inc
Encinitas, California
Local Institution
Greenbrae, California
Ucla-Division Of Hematology/Oncology
Los Angeles, California
Medical Oncology Care Associates
Orange, California
Sharp Clinical Oncology Research
San Diego, California
Local Institution
Vallejo, California
Local Institution
Boca Raton, Florida
Cancer Care Centers Of Florida
Brooksville, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Local Institution
New Port Richey, Florida
Cancer Institute Of Florida
Orlando, Florida
Local Institution
Titusville, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Winship Cancer Institute.
Atlanta, Georgia
Georgia Health Science University
Augusta, Georgia
Orchard Healthcare Research Inc.
Skokie, Illinois
Local Institution
Indianapolis, Indiana
Local Institution
Mishawaka, Indiana
Local Institution
Iowa City, Iowa
Local Institution
Lexington, Kentucky
Local Institution
Louisville, Kentucky
Pikeville Medical Center
Pikeville, Kentucky
Cancer Center Of Acadiana At Lafayette General
Lafayette, Louisiana
Local Institution
Shreveport, Louisiana
Local Institution
Shreveport, Louisiana
Willis Knighton Cancer Center
Shreveport, Louisiana
Dana Farber Cancer Inst
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Capitol Comprehensive Cancer Care Center
Jefferson City, Missouri
Local Institution
Springfield, Missouri
Washington University School Of Medicine
St Louis, Missouri
Local Institution
Las Vegas, Nevada
NYU Clinical Cancer Center
New York, New York
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.